Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage.

OBJECTIVE Cancer cells in the body release soluble and membranous factors that manipulate the tumor environment to facilitate growth and survival. Recent years have provided evidence that small microvesicles that are termed exosomes may play a pivotal role in this process. Exosomes are membrane vesicles with a size of 40-100 nm that are released by both tumor and normal cells and can be found in various body fluids. Tumor-derived exosomes carry functional proteins, mRNAs, and miRNAs and could serve as novel platform for tumor diagnosis and prognosis. However, marker proteins that allow enrichment of tumor-derived exosomes over normal exosomes are less well defined. METHODS We used Western blot analysis and antibody coupled magnetic beads to characterize CD24 and EpCAM as markers for exosomes. We investigated ovarian carcinoma ascites, pleural effusions and serum of breast carcinoma patients. As non-tumor derived control we used exosomes from ascites of liver cirrhosis patients. RESULTS Exosomes could be isolated from all body fluids and contained marker proteins as well as miRNAs. We observed that CD24 and EpCAM were selectively present on ascites exosomes of tumor patients and copurified together on anti-EpCAM or anti-CD24 magnetic beads. In breast cancer patients CD24 was present but EpCAM was absent from serum exosomes. Instead, the intact EpCAM ectodomain was recovered in a soluble form. We provide evidence that EpCAM can be cleaved from exosomes via serum metalloproteinase(s). CONCLUSION Loss of EpCAM on serum exosomes may hamper enrichment by immune-affinity isolation. We suggest that CD24 could be an additional marker for the enrichment of tumor-derived exosomes from blood.

[1]  B. Chauffert,et al.  Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. , 2010, The Journal of clinical investigation.

[2]  J. Bodmer,et al.  Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens. , 1983, Immunology.

[3]  P. Altevogt,et al.  Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease‐dependent ectodomain shedding and exosome secretion , 2008, Journal of cellular biochemistry.

[4]  Richard J. Simpson,et al.  Proteomics Analysis of A33 Immunoaffinity-purified Exosomes Released from the Human Colon Tumor Cell Line LIM1215 Reveals a Tissue-specific Protein Signature* , 2009, Molecular & Cellular Proteomics.

[5]  C. Bordier.  Phase separation of integral membrane proteins in Triton X-114 solution. , 1981, The Journal of biological chemistry.

[6]  Aled Clayton,et al.  Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. , 2007, Cancer research.

[7]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[8]  P. Altevogt,et al.  A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. , 2006, The Biochemical journal.

[9]  H. Stenmark,et al.  Protein sorting into multivesicular endosomes. , 2003, Current opinion in cell biology.

[10]  Ru-Fang Yeh,et al.  Molecular Biomarker Analyses Using Circulating Tumor Cells , 2010, PloS one.

[11]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[12]  William E. Grizzle,et al.  Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.

[13]  G. Kristiansen,et al.  Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. , 2007, Gynecologic oncology.

[14]  T. Whiteside,et al.  Tumor-Derived Microvesicles Induce, Expand and Up-Regulate Biological Activities of Human Regulatory T Cells (Treg) , 2010, PloS one.

[15]  Robert L Moritz,et al.  Exosomes: proteomic insights and diagnostic potential , 2009, Expert review of proteomics.

[16]  G. Kristiansen,et al.  Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis , 2010, Laboratory Investigation.

[17]  William E. Grizzle,et al.  Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells1 , 2007, The Journal of Immunology.

[18]  L. Zitvogel,et al.  Malignant effusions and immunogenic tumour-derived exosomes , 2002, The Lancet.

[19]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[20]  G. Parmiani,et al.  Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.

[21]  Ashley M. Cimino,et al.  Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases , 2010, Breast Cancer Research and Treatment.

[22]  P. Altevogt,et al.  Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. , 1999, Journal of cell science.

[23]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Mack,et al.  Initial activation of EpCAM cleavage via cell-to-cell contact , 2009, BMC Cancer.

[25]  G. Kristiansen,et al.  Tumour Biological Aspects of CD24, A Mucin-Like Adhesion Molecule , 2003, Journal of Molecular Histology.

[26]  Christos Sotiriou,et al.  Circulating tumor cells and emerging blood biomarkers in breast cancer , 2010, Current opinion in oncology.

[27]  Graça Raposo,et al.  The Biogenesis and Functions of Exosomes , 2002, Traffic.

[28]  C. Pilarsky,et al.  CD24 expression is a new prognostic marker in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Altevogt,et al.  Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. , 2009, Cancer letters.

[30]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[31]  Luigi Biancone,et al.  Exosomes/microvesicles as a mechanism of cell-to-cell communication. , 2010, Kidney international.

[32]  P. Altevogt,et al.  L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. , 2006, Cancer letters.

[33]  O. De Wever,et al.  An ex(o)citing machinery for invasive tumor growth. , 2010, Cancer research.

[34]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[35]  P. Möller,et al.  Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. , 1987, Cancer research.

[36]  Dirk Hasenclever,et al.  Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer , 2008, Clinical Cancer Research.

[37]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[38]  Brigitte Mack,et al.  Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.

[39]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[40]  Sascha Keller,et al.  Exosomes: from biogenesis and secretion to biological function. , 2006, Immunology letters.

[41]  Aled Clayton,et al.  Cancer exosomes trigger fibroblast to myofibroblast differentiation. , 2010, Cancer research.